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Neglected diseases aNd iNNovatioN iN south asia
Multidrug resistant enteric fever in South Asia: 
unmet medical needs and opportunities
Investments in newer diagnostics and antimicrobial treatments are critical to improve management 
of enteric fever in South Asia, say Christopher Parry and colleagues
Enteric fever (typhoid) is the com-monest bacterial bloodstream infection in South Asia.1 It is caused by Salmonella enterica serovars Typhi and Paratyphi A. 
Despite progress in controlling enteric fever 
in several parts of the world, it remains an 
important public health burden in South 
Asia. The incidence is estimated to be over 
100 per 100 000 population. Around seven 
million people are affected each year in 
South Asia with about 75 000 deaths.2 
However, these figures are likely to be an 
underestimate because of limitations in 
population based surveillance systems and 
reliable diagnostic methods.2-4
We discuss the challenges in managing 
enteric fever in South Asia in the context 
of growing antimicrobial resistance and 
highlight the need for sustained focus on 
improvements in diagnosis and treatment 
as part of an integrated control strategy.
Growing antimicrobial resistance
Since the first reports of chloramphenicol 
resistance in S Typhi in the 1970s, resist-
ance to each new antimicrobial treatment 
has emerged relentlessly.5 Multidrug resist-
ance—that is, resistance to chlorampheni-
col, amoxicillin, and co-trimoxazole—is 
found in many areas of South Asia and was 
associated with numerous outbreaks in the 
late 1980s and early 1990s.
Fluoroquinolones then emerged as the 
treatment of choice.6 7 Widespread use 
of second generation fluoroquinolones 
(ciprofloxacin and ofloxacin-levofloxacin) 
has now led to decreased susceptibility 
o f  o rga n i s m s 5 a c ro s s  t h e  I n d i a n 
subcontinent.6 8 Complete fluoroquinolone 
resistance, including resistance to the later 
generation fluoroquinolone gatifloxacin, 
emerged sometime after 2010 and has 
been associated with treatment failures 
and prolonged fever.5 8-10 The doses of 
fluoroquinolone used in early treatment 
studies, although giving a clinical cure, 
may have been insufficient to prevent the 
emergence of first step mutants.
In recent data from Pakistan published 
as part of the surveillance for enteric fever 
in Asia project (SEAP), over half of all S 
Typhi isolates were multidrug resistant. 
Fluoroquinolone resistance was noted 
in nearly 90% of S Typhi and S Paratyphi 
isolates.11 A longitudinal study of typhoid 
fever trends at three large hospitals in 
India showed a fall in resistance rates 
for ampicillin, chloramphenicol, and 
co-trimoxazole between 2000 and 2014, as 
resistance to more widely used antibiotics 
has risen.12 Near universal resistance to 
ciprofloxacin has been observed in recent 
isolates from India.12 13
Azithromycin remains an effective 
oral option. However, given its wide use 
in a variety of clinical presentations, 
including suspected typhoid fever and 
respiratory infections, there is concern 
about potential emergence of resistant 
strains.5 14 Third generation cephalosporins 
such as ceftriaxone and cefixime are 
increasingly used, with very low resistance 
reported to these drugs until recently.12 
Since 2016, outbreaks of extensively drug 
resistant S Typhi strains that are resistant 
to ceftriaxone and cefixime have been 
reported in parts of Pakistan.15 This severely 
limits the antimicrobial treatment options, 
and salvage therapy with intravenous 
carbapenems may be needed.15 These drugs 
are expensive and often inaccessible in low 
resource settings.
Inadequate diagnostic tools
Typhoid presents with undifferentiated 
fever in the initial stages and is often 
 confused with other common causes of 
acute fever in tropical regions such as 
malaria, dengue, chikungunya, Zika, rick-
ettsial infection, leptospirosis, and brucel-
losis.5 16 The overlap of clinical features with 
other conditions makes clinical diagnosis 
difficult. Patients presenting with undiffer-
entiated fever are often started on empirical 
treatment, once malaria has been excluded, 
without diagnostic confirmation. As such, 
diagnosis may be missed or delayed, result-
ing in inappropriate treatment.
Untreated, typhoid causes a prolonged 
and debilitating febrile illness that can 
last for several weeks.5 The mortality from 
untreated typhoid has been estimated at 
10% or more.17 Patients can develop life 
threatening complications such as intestinal 
perforation, gastrointestinal bleeding, 
and, less commonly, encephalopathy and 
shock. There is also a risk of relapse and 
chronic faecal carriage. With appropriate 
antimicrobial treatment, symptoms typically 
resolve within a week and risk of mortality 
is below 1%.18 19
Inadequate diagnostic tests complicate 
the management of typhoid fever.20 Isolation 
of S Typhi on blood culture is required for 
a definitive diagnosis. Blood culture is also 
the only diagnostic method that permits 
monitoring for drug resistance. However, 
its sensitivity is suboptimal, ranging 
between 40% and 80%. A systematic review 
and meta-analysis of 40 studies found a 
relation between specimen volume and 
blood culture sensitivity, with increase in 
sensitivity from 51% (2 mL specimen) to 
65% (10 mL specimen). Subgroup analysis 
showed significant heterogeneity by 
patient age. Previous antimicrobial use and 
specimen collection beyond the first week of 
symptoms reduced the sensitivity by nearly 
30%.21 Clinicians’ use of blood culture 
also varies considerably. In a prospective 
study from Nepal, of 4309 patients with 
acute fever, over half received a provisional 
clinical diagnosis of enteric fever, but only 
4% of these patients had culture confirmed 
S Typhi infection.22 Blood culture requires 
reliable laboratory facilities and is often not 
feasible in low resource settings.
Key messages
•   Relentless emergence of antimicrobial 
resistance has led to treatment fail-
ures and limited treatment choices for 
typhoid fever in South Asia
•   A new conjugate vaccine approved 
in 2018 offers an important tool to 
control typhoid in South Asia
•   Investments in research and develop-
ment of rapid diagnostic tests and 
new treatments must be prioritised.
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In the absence of reliable and quick 
diagnostic tests, the Widal test is widely 
used by clinicians in South Asia to diagnose 
typhoid.23 It is a serological test that relies 
on a fourfold or greater rise in antibody 
titre against the H and O antigens of S 
Typhi between the acute and convalescent 
stages of disease to confirm diagnosis and 
is intended as a tool to increase the index 
of suspicion for typhoid. Difficulties remain 
with the test’s performance and with 
interpretation of results, particularly when 
it is used as a standalone test in the acute 
stage. Cross reactivity with other infectious 
agents24 may result in false positive results 
and lead to overdiagnosis of typhoid fever. 
A striking example of this was noted in post-
earthquake Nepal, where a cross reaction 
of the test with rickettsia (scrub typhus) 
infection resulted in misdiagnosis and 
delay in initiating appropriate treatment. 
Ceftriaxone was prescribed for typhoid 
rather than doxycycline, which is the drug 
of choice for scrub typhus.25
Control measures fall short
Enteric fever is transmitted through food 
and water contaminated with human 
waste. It can be eliminated with interven-
tions such as access to potable water, safe 
sanitation, and hygienic food production 
practices. With improvements in water 
quality and sanitation, countries in North 
America and Europe succeeded in eliminat-
ing typhoid as a public health problem.
South Asia has made considerable 
progress in improving access to sanitation 
facilities over the past 25 years.26 The 
proportion of people with access to improved 
sanitation increased from 25% in 1990 to 
48% in 2015 and the proportion of people 
who practise open defecation fell from 
65% to 34%. Three countries—Maldives, 
Pakistan, and Sri Lanka—have met the 
millennium development goals’ sanitation 
target, with over 60% of the population 
having access to toilets. Bangladesh, 
Bhutan, and Nepal have made good 
progress as well. India accounts for over 
60% (596 million) of the global population 
who practise open defecation. The Indian 
government launched the Swacch Bharat 
Mission in 2014 with the goal of reaching 
universal sanitation coverage by 2019 
although this may be difficult to achieve. 
The programme has intensified efforts to 
raise awareness on the need for improved 
sanitation and safe water, construct 
household toilets, and systematically 
monitor the creation of villages and districts 
that have no open defecation.
Access to uncontaminated water in South 
Asia has increased from 73% to 93% since 
1990. However, over 134 million people still 
do not have access to safe drinking water. 
Between 68% and 84% of water sources in 
South Asia are estimated to be contaminated 
with bacteria and/or chemicals.26 27
Rapid unplanned urbanisation in South 
Asia has compounded the challenge of 
ensuring safe drinking water supply and 
access to toilets. Urban-rural disparities in 
access to improved water and sanitation 
facilities are pronounced, with rural 
households more commonly practising 
open defecation.28 Disparities in sanitation 
coverage are also observed between rich 
and poor households as well as by sex, 
education level, and caste.29
A small subset of patients with typhoid 
become chronic carriers, with faecal 
shedding of bacteria for several weeks after 
symptoms have resolved. These patients are 
a potential source of infection to others in 
the community. Despite clear links between 
typhoid and consumption of street foods in 
South Asia, there is no systematic screening 
for chronic carriers among food handlers. 
Few studies have evaluated the effectiveness 
of antimicrobial regimens in restricting 
faecal shedding.
New developments in prevention, diagnosis, 
and treatment
Alongside sustained efforts to improve sani-
tation and water safety, vaccination prom-
ises to aid typhoid control in South Asia in 
the coming years. Improving case manage-
ment of typhoid fever requires development 
of alternative antimicrobial treatments 
and new diagnostics. Salmonella spp, par-
ticularly those that are resistant to fluoro-
quinolones, are among the high priority 
pathogens identified by WHO as requiring 
urgent research and new antimicrobials.30
Regional collaboration will be critical 
to sustain focus on typhoid elimination, 
boost research and development of new 
interventions, improve surveillance systems, 
and foster transfer of knowledge between 
nations.
Vaccines
Vaccination can have an important role in 
reducing the disease burden and stalling 
the emergence of resistant strains. Until 
recently, two typhoid vaccines have been 
available: an oral vaccine (Ty21a vaccine) 
supplied in enteric coated capsules taken 
once daily for three days, and the injectable 
Vi polysaccharide vaccine (ViCPS vaccine) 
given intramuscularly in a single dose. The 
protective efficacy wanes over time, and 
revaccination is recommended every three 
years.31 32 Neither vaccine is recommended 
in children younger than 2 years, making 
it difficult to incorporate them into routine 
vaccination programmes in endemic set-
tings, and so vaccines have been largely 
used in travellers to low and middle income 
countries.
In January 2018, WHO prequalified 
a conjugated Vi polysaccharide vaccine 
Typbar-TCV, indicating it meets the 
required standards of safety, efficacy, 
and quality to be rolled out in routine 
childhood immunisation programs in 
endemic countries.33 The vaccine, which 
was developed by the Indian drug company 
Bharat Biotech, has longer and higher levels 
of immunogenicity than the ViCPS vaccine 
and is safe to use in infants older than 6 
months. In October 2017, the Strategic 
Advisory Group of Experts (SAGE) on 
immunisation recommended routine use of 
the vaccine in typhoid endemic countries as 
a single dose in children aged 6- 23 months, 
and for catch-up vaccination in children 
aged 2-15 years.31 34
The vaccine has been registered in India 
and Nepal, but implementation of routine 
vaccination across South Asia will take time 
dependent on further approvals, availability, 
and funding. Post-licensing monitoring of 
effectiveness, persistence of protection, and 
safety will also be important.35 The typhoid 
conjugate vaccine does not protect against S 
Paratyphi A, which is responsible for up to 
a fifth of cases of enteric fever. Developing a 
combination vaccine that provides complete 
protection against salmonella infections 
must be prioritised.
Diagnostics
Reliable, rapid diagnostics that do not 
require sophisticated laboratory infra-
structure are needed to improve antibiotic 
stewardship and generate critical data on 
the burden of disease.
A Cochrane review in 2017 (37 studies, 
5080 participants) evaluated the diagnostic 
accuracy of available point-of-care rapid 
diagnostic tests for enteric fever.36 Most 
studies evaluated three tests and their 
variants: TUBEX (14 studies); Typhidot (22 
studies); and the KIT Test-It Typhoid (nine 
studies). These are all antibody tests on 
blood to detect S Typhi infection. None of 
the included studies evaluated a test for S 
Paratyphi A infection. Most of the studies 
were in South Asia: India (10 studies), 
Bangladesh (five), Pakistan (four). The 
quality of the studies was generally low, 
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with two thirds including patients who 
would not typically be tested for this disease. 
The review concluded that the current tests 
are not sufficiently accurate to replace blood 
culture as a diagnostic test for enteric fever.
Newer diagnostic approaches such 
as serodiagnostic antigens, nucleic 
acid amplification tests, proteomics, 
metabolomics, and host response gene 
patterns are being explored20 but are still a 
considerable way from being used in routine 
practice. Any new tests will also need to be 
shown to be cost effective before they are 
implemented in South Asia.
Effective case management
No recent national or regional guidelines 
exist for treatment of enteric fever, and 
evidence based diagnostic pathways and 
empirical treatment regimens suited to 
South Asia are urgently needed to support 
clinicians.
Antimicrobial resistance patterns are 
highly dynamic and need to be considered 
carefully. Clinicians must be aware of local 
resistance patterns and modify treatment 
based on antibiotic susceptibility results 
in confirmed cases of enteric fever. Short 
fever clearance times and low relapse 
rates have been reported with oral 
azithromycin, and it may be an effective 
treatment.7 Lack of resistance against third 
generation cephalosporins, principally 
parenteral ceftriaxone and oral cefixime, 
in S Typhi and S Paratyphi A make these 
a reliable choice for suspected typhoid, 
particularly in regions with known 
resistance. For extensively drug resistant 
strains, potential antimicrobials include 
piperacillin-tazobactam, ceftazidime-
avibactam, carbapenems (such as 
meropenem, imipenem, or ertapenem), 
tigecycline, fosfomycin, and colistin. These 
are given parenterally, but there is limited 
experience and evidence on their use in 
enteric fever.
Antimicrobial combinations are an 
option when the diagnosis is unclear or 
when polymicrobial infection is likely. For 
example, in areas where both typhoid and 
Rickettsia spp or Orientia tsutsugamushi 
infections are common causes of acute 
febrile illness, a combination of ceftriaxone 
and doxycycline may be appropriate as 
initial empirical therapy in adults, especially 
if confirmatory diagnostic testing is not 
available or while results are awaited.37 
Similarly, combination treatment may be 
required in typhoid associated intestinal 
perforation to treat S Typhi and other 
intestinal organisms causing peritonitis.
Preventing the emergence of resistance 
has been an important justification for 
the use of combination therapies in 
tuberculosis, HIV, and malaria. In principle, 
when antibiotic monotherapy is used, the 
drug susceptible fraction of the population 
is killed, while the resistant subpopulation 
replicates and becomes dominant. The use 
of two or more antimicrobials makes this less 
likely unless there is background resistance 
to both antimicrobials. For example, S Typhi 
and S Paratyphi A isolates acquire decreased 
susceptibility to fluoroquinolones by point 
mutations. Fluoroquinolone doses that are 
effective against the wild type isolates but 
fail to supress the first step mutants can 
select for the mutant strains. Combining 
a fluoroquinolone with a drug targeting a 
different pathway may prevent first step 
mutants from replacing the wild type.
Drug combinations, however, are costlier 
and have an increased risk of adverse events. 
Combining the right drugs in the appropriate 
doses will be critical.38 An inappropriate 
combination may inadvertently select 
for new resistance profiles. Fixed dose 
combinations of relevant antimicrobials 
are available in India, but there has 
been relatively little research on the 
pharmacokinetic and pharmacodynamic 
parameters that predict the successful 
treatment of typhoid and few clinical trials 
of potential combinations.39
The priorities for future research include 
development of new treatments; in vitro 
assessments of old and new drugs and 
drug combinations against a relevant 
panel of isolates, including extensively 
drug resistant typhoid; and clinical trials 
of salvage regimens for multidrug resistant 
enteric fever, antimicrobial combinations for 
suspected and confirmed enteric fever, and 
antimicrobial regimens to prevent chronic 
carriage. New treatments and diagnostics, 
together with better vaccines and sanitation, 
will be essential for elimination of typhoid 
in South Asia.
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